Non-repudiation analysis using LySa with annotations

This work introduces a forma lanalysis of the non-repudiatio property for security protocols. Protocols are modelled in the process calculus LySa, using an extended syntax with annotations. Non-repudiation is verified using a Control Flow Analysis, following the same approach of Buchholtz and Gao for authentication and freshness analyses. The result is an analysis that can statically check the protocols to predict if they are secure during their execution and which can be fully automated

POSTER-TRIPLEX : verifying data minimisation in communication systems

Systems dealing with personal information are legally required to satisfy the principle of data minimisation. Privacy-enhancing protocols use cryptographic primitives to minimise the amount of personal information exposed by communication. However, the complexity of these primitives and their interplay makes it hard for non-cryptography experts to understand the privacy implications of their use. In this paper, we present TRIPLEX, a framework for the analysis of data minimisation in privacy-enhancing protocols. Keywords: Data minimisation; Coalition Graphs; Detectability; Linkabilit

Formal Analysis of Privacy for Anonymous Location Based Services

Abstract. We propose a framework for formal analysis of privacy in location based services such as anonymous electronic toll collection. We give a formal definition of privacy, and apply it to the VPriv scheme for vehicular services. We analyse the resulting model using the ProVerif tool, concluding that our privacy property holds only if certain conditions are met by the implementation. Our analysis includes some novel features such as the formal modelling of privacy for a protocol that relies on interactive zero-knowledge proofs of knowledge and list permutations.

A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

ONYX-015 is an adenovirus with the E1B 55-kDa gene deleted, engineered to selectively replicate in and lyse p53-deficient cancer cells while sparing normal cells. Although ONYX-015 and chemotherapy have demonstrated anti-tumoral activity in patients with recurrent head and neck cancer, disease recurs rapidly with either therapy alone. We undertook a phase II trial of a combination of intratumoral ONYX-015 injection with cisplatin and 5-fluorouracil in patients with recurrent squamous cell cancer of the head and neck. There were substantial objective responses, including a high proportion of complete responses. By 6 months, none of the responding tumors had progressed, whereas all non-injected tumors treated with chemotherapy alone had progressed. The toxic effects that occurred were acceptable. Tumor biopsies obtained after treatment showed tumor-selective viral replication and necrosis induction.</p